We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+13.3%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.83B
AUM Growth
-$193M
Cap. Flow
-$2.01B
Cap. Flow %
-41.54%
Top 10 Hldgs %
42.39%
Holding
141
New
14
Increased
13
Reduced
19
Closed
37

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$95.6M
2
SPRY icon
ARS Pharmaceuticals
SPRY
+$71.9M
3
AMED
Amedisys
AMED
+$70M
4
PCVX icon
Vaxcyte
PCVX
+$27.5M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$24.7M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$94.9M
2
BIIB icon
Biogen
BIIB
+$88.1M
3
AERI
Aerie Pharmaceuticals
AERI
+$73.5M
4
LUNG icon
Pulmonx
LUNG
+$62M
5
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$55.5M

Sector Composition

Rank Sector Weight
1 Healthcare 56.42%
2 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMGN
26
DELISTED
Immunogen Inc
IMGN
$31.5M 0.65%
6,358,314
-7,381,891
-54% -$40M
KURA icon
27
Kura Oncology
KURA
$964M
$29.6M 0.61%
2,383,000
+163,872
+7% +$2.38M
BLU
28
DELISTED
BELLUS Health Inc.
BLU
$29.4M 0.61%
3,581,000
+500,000
+16% +$4.66M
TERN
29
DELISTED
Terns Pharmaceuticals
TERN
$29M 0.6%
2,851,287
+991,287
+53% +$6.6M
NAMS icon
30
NewAmsterdam Pharma
NAMS
$3.7B
$27M 0.56%
+2,480,199
New +$24.7M
SWTX
31
DELISTED
SpringWorks Therapeutics
SWTX
$26.9M 0.56%
1,033,000
+216,006
+26% +$5.32M
VIGL
32
DELISTED
Vigil Neuroscience
VIGL
$25.7M 0.53%
2,052,010
-2,784
-0.1% -$34.2K
EOLS icon
33
Evolus
EOLS
$377M
$24.9M 0.52%
3,319,000
-2,071,103
-38% -$16M
ACH
34
Accendra Health
ACH
$266M
$23M 0.48%
+1,179,000
New +$23M
RAIN
35
DELISTED
Rain Oncology Inc. Common Stock
RAIN
$22.4M 0.46%
+2,796,261
New +$17.6M
DNLI icon
36
Denali Therapeutics
DNLI
$3.7B
$22.2M 0.46%
+800,000
New +$23.8M
RVMD icon
37
Revolution Medicines
RVMD
$39.6B
$21.2M 0.44%
891,587
-2,000,000
-69% -$42.5M
DAWN
38
DELISTED
Day One Biopharmaceuticals
DAWN
$20.7M 0.43%
964,033
-67,967
-7% -$1.39M
TARS icon
39
Tarsus Pharmaceuticals
TARS
$2.61B
$19.4M 0.4%
1,324,214
– –
APEN
40
DELISTED
Apollo Endosurgery, Inc.
APEN
$17.4M 0.36%
1,750,000
– –
PRME icon
41
Prime Medicine
PRME
$565M
$16.4M 0.34%
+885,314
New +$16M
DALS
42
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$16M 0.33%
1,600,000
– –
KRYS icon
43
Krystal Biotech
KRYS
$10.5B
$13.9M 0.29%
175,000
– –
INSM icon
44
Insmed
INSM
$23.5B
$13.3M 0.27%
664,146
-296,338
-31% -$5.73M
OMIC
45
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
$13M 0.27%
215,029
-20,905
-9% -$1.4M
ATEC icon
46
Alphatec Holdings
ATEC
$1.31B
$12.9M 0.27%
1,046,791
-1,486,001
-59% -$15M
PCRX icon
47
Pacira BioSciences
PCRX
$1.01B
$11.3M 0.23%
292,000
– –
NUVB icon
48
Nuvation Bio
NUVB
$2.02B
$11.2M 0.23%
5,854,860
+5,609,500
+2,286% +$11.3M
KZR
49
DELISTED
Kezar Life Sciences
KZR
$10.1M 0.21%
+143,000
New +$10.6M
ALEC icon
50
Alector
ALEC
$167M
$9.74M 0.2%
1,055,192
– –
1
2
3 4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q4 2022 Portfolio in Review

As of Q4 2022, Deerfield Management held 141 positions worth $4.83B, down 3.8% from $5.02B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Deerfield Management withdrew a net $2.01B in Q4 2022, closing 37 positions and reducing 19 holdings. Its most notable exit was Gilead Sciences, an estimated $94.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, up from 53% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Amylyx Pharmaceuticals worth $99.5M.

  • Deerfield Management's largest Q4 2022 buy was Amylyx Pharmaceuticals: 2,693,000 shares worth $99.5M.
  • Deerfield Management added most to Amedisys in Q4 2022, an estimated $70M increase.
  • Deerfield Management's biggest Q4 2022 reduction was Silk Road Medical, Inc. Common Stock, cutting an estimated $55.5M.
  • Deerfield Management fully exited Gilead Sciences in Q4 2022, selling an estimated $94.9M.
  • Deerfield Management's ten largest holdings make up 42% of its $4.83B portfolio in Q4 2022.
  • Deerfield Management opened 14 new positions and closed 37 in Q4 2022.
  • Deerfield Management's portfolio value fell 3.8% quarter-over-quarter to $4.83B.

Based on Deerfield Management's 13F filing for Q4 2022, filed 14 Feb 2023.